Category: Business

Sputnik Light will be an important part of India’s vaccination program and the fight against mutations of COVID, including Omicron.

Sputnik Light has been authorized in more than 30 countries with total population of over 2.5 billion people.

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the Russian one-shot Sputnik Light vaccine against coronavirus has been authorized by the Drug Controller General of India (DCGI).

Thus Sputnik Light has been registered in more than 30 countries with total population of over 2.5 billion people. A number of countries, including Argentina, Bahrain, UAE, San Marino and Philippines, have already authorized Sputnik Light as a universal booster.

A preliminary study of the Gamaleya Center has found that Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron, which is comparable to titers observed after Sputnik V against wild-type virus, associated with high levels of protection.

A unique comparative study[1] conducted at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center has shown that Sputnik V vaccine demonstrates more than 2 times higher titers of virus neutralizing antibodies to Omicron (B.1.1.529) variant than 2 doses of Pfizer vaccine (2.1 times higher in total and 2.6 times higher 3 months after vaccination).

The study was conducted in the equal laboratory conditions on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus neutralizing activity against Wuhan variant. Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).

Based on the data collected by the Spallanzani Institute and results of previous studies, heterologous (“mix & match”) boosting with Sputnik Light is the best solution to increase other vaccines’ efficacy and extend the booster protection period as optimal adenoviral platform configuration provides better protection against Omicron and other mutations.

Sputnik Light is based on recombinant human adenovirus serotype number 26 (the first component of Sputnik V). A one-shot vaccination regimen of Sputnik Light provides for ease of administration and helps to increase efficacy and duration of other vaccines when used as a booster shot.

Dr. Reddy’s Laboratories, a major partner of RDIF in India, has conducted local clinical trials of Sputnik Light in India. Positive data from these trials have been presented to India’s regulator and contributed to the positive decision by DCGI.

Clinical studies and the real-world data in many countries have demonstrated Sputnik Light is a safe and effective vaccine when used both on a standalone basis and as a booster.

A study in Argentina on heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino has demonstrated that each “vaccine cocktail” combination with Sputnik Light provided higher antibody titer on 14th day after administering the second dose as compared to original homogenous (same vaccine as first and second dose) regimens of each of the vaccines.

Sputnik Light will add to India’s national vaccine portfolio and join Sputnik V, which was approved in the country in April 2021. India is the leading production hub for Sputnik V.

Sputnik V and Sputnik Light are based on a safe and effective human adenoviral vector platform and have not been associated with rare serious adverse events following vaccination, such as myocarditis or pericarditis. The highest safety and efficacy of Sputnik V and Sputnik Light was demonstrated in more than 30 studies and real-world data from more than 60 countries.

Sputnik V has been authorized in 71 countries with total population of over 4 bn people. To facilitate the necessary production capacities, RDIF has reached agreements with the leading Indian pharmaceutical companies, including Serum Institute of India – the world’s largest vaccine producer, as well as Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Authorization of Sputnik Light in India is another major step in successful cooperation between Russia and India in the fight against COVID. Sputnik Light has proven to be safe and effective both as a standalone vaccine and a universal booster shot to vaccines of other producers, helping to induce stronger immune response as compared to two shots of the same vaccine. The heterologous boosting approach using Sputnik Light is the solution to increase efficacy and duration of other vaccines, including against Omicron variant.”

Chennai, Tamil Nadu, India
Saveetha Oral Cancer Institute conducts a free cancer screening and awareness program in commemoration of world cancer day on 4th February 2022. Cancer becomes the second cause of death globally. Despite the tremendous developments in the field of diagnosis and treatment methods, the incidence of cancer has spiked in the last two decades in the Indian subcontinent. Being a pioneer as a dental college with a separate oral oncology unit, Saveetha dental college conducts free screening and treatment programs for the patients suffering from Oral cancer on World Cancer Day. With the latest technologies and skilful hands, Saveetha Oral Cancer Institute (SOCI) provides the utmost care for the patients. As the saying reveals, Prevention is better than cure, SOCI conducts camps to create awareness and aids in identifying the disease at a very early stage which leads to the best prognosis. While focusing on treatment, the preventive measures of such dreadful disease are also emphasized to the public.

MILPITAS, Calif., Feb. 5, 2022 /PRNewswire/ — SEMI, the industry association serving the global electronics design and manufacturing supply chain, today commended the passage of the America COMPETES Act of 2022 by the United States House of Representatives. The bill includes funding for the Creating Helpful Incentives to Produce Semiconductors for America (CHIPS) Act, earmarked to strengthen U.S. semiconductor manufacturing and research.

“We are very pleased to see the House pass the America COMPETES Act of 2022 including robust funding for the CHIPS Act programs,” said Ajit Manocha, SEMI president and CEO. “This bill also includes an important clarification to ensure equipment and materials suppliers can access the Section 9902 grant program. With this provision, the CHIPS programs will attract new manufacturing facilities – including chip fabs and facilities for back-end and upstream suppliers – and support technologies and innovation critical to numerous industries in the U.S. and around the globe. This bill will strengthen the semiconductor supply chain in the United States to meet the challenges of the twenty-first century as well as bolster crucial workforce development programs. We look forward to working with Congress and the Biden Administration to quickly enact this funding into law.”

“We continue to urge quick action on the Advanced Manufacturing Investment Credit and restoration of the ability to immediately deduct research expenses which was removed at the start of this year,” Manocha said.

Visit SEMI Global Advocacy to learn more about public policy efforts and developments, and SEMI Workforce Development for more information on efforts to address the microelectronics industry’s talent needs.

About SEMI

SEMI® connects more than 2,400 member companies and 1.3 million professionals worldwide to advance the technology and business of electronics design and manufacturing. SEMI members are responsible for the innovations in materials, design, equipment, software, devices, and services that enable smarter, faster, more powerful, and more affordable electronic products. Electronic System Design Alliance (ESD Alliance), FlexTech, the Fab Owners Alliance (FOA), the MEMS & Sensors Industry Group (MSIG) and SOI Consortium are SEMI Strategic Technology Communities. Visit www.semi.org to learn more, contact one of our worldwide offices, and connect with SEMI on LinkedIn and Twitter.

(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)

Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world

Sputnik V has been authorized in 71 countries with total population of over 4 billion people.

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus has been granted full permanent approval by Russia’s Health Ministry. It had previously held temporary emergency use authorization (EUA) from the Russian regulator.

Sputnik V was authorized on August 11, 2020, becoming the world’s first vaccine against COVID-19 to be granted emergency use authorization. Sputnik V has been authorized in 71 countries with a total population of over 4 billion people. Its one-component version, Sputnik Light, is authorized in over 30 countries, both as a standalone vaccine and a universal booster to other vaccines.

Sputnik V and Sputnik Light are based on a safe and effective human adenoviral vector platform and have not been associated with rare serious adverse events following vaccination, such as myocarditis or pericarditis. The highest safety and efficacy of Sputnik V and Sputnik Light was demonstrated in more than 30 studies and real-world data from more than 60 countries.

A unique comparative study[1] conducted at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center has shown that Sputnik V vaccine demonstrates more than 2 times higher titers of virus neutralizing antibodies to Omicron (B.1.1.529) variant than 2 doses of Pfizer vaccine (2.1 times higher in total and 2.6 times higher 3 months after vaccination).

The study was conducted in the equal laboratory conditions on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus neutralizing activity against Wuhan variant. Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).

Based on the data collected by the Spallanzani Institute and results of previous studies, heterologous (“mix & match”) boosting with Sputnik Light is the best solution to increase other vaccines’ efficacy and extend the booster protection period as optimal adenoviral platform configuration provides better protection against Omicron and other mutations.

A preliminary study of the Gamaleya Center has found that Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron, which is comparable to titers observed after Sputnik V against wild-type virus, associated with high levels of protection.

Sputnik Light is based on recombinant human adenovirus serotype number 26 (the first component of Sputnik V). A one-shot vaccination regimen of Sputnik Light provides for ease of administration and helps to increase efficacy and duration of other vaccines when used as a booster shot.

Clinical studies and the real-world data in many countries have demonstrated Sputnik Light is a safe and effective vaccine when used both on a standalone basis and as a booster.

A study in Argentina on heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino has demonstrated that each “vaccine cocktail” combination with Sputnik Light provided higher antibody titer on 14th day after administering the second dose as compared to original homogenous (same vaccine as first and second dose) regimens of each of the vaccines.

[1] https://www.medrxiv.org/content/10.1101/2022.01.15.22269335v1

– Acquisition of US FDA Approved State-of-the-Art Manufacturing Facility with Approximately 68,000 Square Feet On a 14 Acre Campus in the Heart of New Jersey – Also Known as “the Medicine Chest” of America

– Capabilities include Formulation Development, Manufacturing of Soft Gels, Powders, Tablets, Capsules, Liquid Drugs, Controlled Substance (schedule II – IV), Packaging, and Warehousing

– Enabling APNAR Pharma to Transition into a Fully Integrated Global Company with R&D, and Manufacturing in the United States of America as well as India

– Collaborative Business Model Allows APNAR Pharma to Provide Contract Manufacturing Services in Addition to Manufacturing APNAR Pharma’s Own Portfolio

EAST WINDSOR, N.J., Feb. 3, 2022 /PRNewswire/ — APNAR Pharma LP (APNAR) headquartered in Chino, CA has acquired East Windsor, NJ based Aurex Laboratories (Aurex) for an undisclosed amount. This acquisition enhances APNAR’s capabilities, scale, and global footprint and broadens APNAR’s pipeline.

Dharmesh Patel, President of APNAR said, “As part of our well-defined strategy and commitment of having manufacturing in the United States of America, we are excited to acquire Aurex. This milestone will position APNAR as a company with global footprint in the US and India.”

Sanjay Bhargav, COO of APNAR added, “In addition to adding state-of-the-art facility to APNAR’s capabilities in the US, we are pleased to welcome to APNAR an amazing team that is experienced, highly capable, and dedicated including scientists, manufacturing, regulatory, and project management personnel.”

“In addition to developing and manufacturing APNAR’s own products, we are looking forward to working in a collaborative manner with other companies for contract and co-development and contract manufacturing,” added Patel.

“We look forward to manufacturing APNAR’s 5 ANDAs and other drugs in the US to ensure supply chain security and excellence,” added Bhargav.

Nailesh Bhatt acted as a strategic advisor to both Aurex Laboratories and APNAR Pharma.

About APNAR Pharma LP

Headquartered in Chino, California, APNAR Pharma is a privately owned, rapidly growing pharmaceutical company. We develop, manufacture, package, sell, market, and distribute generic pharmaceuticals and OTCs. APNAR has R&D and manufacturing facilities in East Windsor, NJ, United States and Gavasad, Gujarat, India.

www.apnarpharma.com

(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)

TORRANCE, Calif., Feb. 2, 2022 /PRNewswire/ — Phenomenex, a global life sciences company that offers analytical chemistry solutions for separation and purification, proudly marks its 40^th anniversary in 2022 with a new mission statement and several exciting strategic initiatives that will deliver an even greater experience for both customers and associates.

On this day in 1982, Phenomenex was born. Over the last four decades what started as a small idea in a garage has grown into a global corporation with more than 1,200 associates who are laser-focused on serving customers better than anyone else. Today, the company provides world-class 24/7 support to customers in the biopharmaceutical, pharmaceutical, environmental, food, clinical research, cannabis, chemicals and fuels industries and more. Its vast portfolio of award-winning laboratory consumables – including liquid chromatography (LC) columns, gas chromatography (GC) columns, sample preparation products such as SPE, SLE, and more – is helping to accelerate science and give researchers the tools they need to improve global health and wellbeing.

“Everything we do is helping contribute to something much bigger than ourselves”, explains Matt Turner, President of Phenomenex who shares a special video message to celebrate the 40-year milestone. “Our solutions are helping scientists solve some of the world’s toughest challenges, and in 2022 we will continue to serve our customers with high-quality products and service, and we have big ambitions and exciting plans to get into some new areas in the future.”

On its 40th birthday, Phenomenex also celebrates a refreshed mission statement:

“Keeping scientists at the heart of our everyday through unforgettable support and standout technology to build a brighter future together.”

An evolution of the original, the new statement honors the founding principles with a new promise to customers of today and the future.

After 40 years in the business, it’s clear Phenomenex’s magic is its people. “I come to work every day feeling lucky to be a part of such a special place. Among our people, there’s an undeniable care for customers, strong sense of teamwork and an impressive level of expertise”, says Turner.  Whether hand-delivering a column for an urgent project, spending extra time to troubleshoot a new method for a customer, or bringing laughter to labs all over the globe, the Phenomenex team takes its work seriously, but is known for celebrating the fun side of science every chance they get.

“As we celebrate the organization’s 40th anniversary it’s not only a time to reflect on all that we’ve accomplished and where we’ve come from, but also a time to focus on where we’re going next”, concludes Turner. “We have great potential to have a greater impact and I look forward to continuing to work together with our customers to understand their needs, to co-create solutions, and to help them in our shared pursuit to create a brighter future for humanity.”

About Phenomenex

Phenomenex is a global technology leader committed to developing analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information, visit phenomenex.com or the company’s blog at scienceunfiltered.com; follow Phenomenex on LinkedIn, Twitter or Facebook.

Media Conact:

Kari Kelly

karik@phenomenex.com

Logo – https://mma.prnewswire.com/media/812765/Phenomenex_Logo.jpg

(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)

The real estate sector did not get anything directly from the Budget 2022-23, except for the announcement related to affordable housing. However, the realtors are showing optimism based on the Government’s stance toward boosting economic growth and spending on infrastructural development.

Migsun Group, one of the renowned names in real estate, has announced that it has completed sales of Rs. 550 crore in Q3 FY21-22 and is targeting another Rs. 700 crore by the end of Q4 FY 21-22. The Group informed that sales were achieved from projects across the cities, including Noida, Ghaziabad, and Lucknow.

After achieving sales of 1014 units of residential, commercials and villas in Q3 FY 21-22, the Group has kept the target of Q4 at 1400 units cumulatively. The sales were majorly in Migsun Janpath (Lucknow), Migsun Ultimo (Greater Noida), Migsun WYN (Greater Noida), Migsun Atharva (Raj Nagar Extension, Ghaziabad), Migsun Kiaan (Vasundhra, Ghaziabad), Migsun Vilaasa (Greater Noida West), and Migsun Chambers.

Commenting on the sector’s performance, Yash Miglani, MD, Migsun Group, said, “After coming to a halt in 2020, the year 2021 got off to a better start, but the second wave hit the market in the first few months; nevertheless, the sector enjoyed a resurgence after June 2021, fueled by record-low home loan interest rates, good projects, and reasonable pricing. As the year continued, the sales figures improved significantly. However, we have been able to achieve good sales numbers even during the challenging COVID times due to our impeccable delivery image.”

Even during the lockdown in 2021, the Group sold over 150 units amounting to approximately Rs. 80 crore in the period from April 22 till May 18; the commercial and residential units were from the projects located in Greater Noida and Raj Nagar Extension (Ghaziabad).

The Group’s commercial projects perform equally well compared to the residential projects. Talking about the importance of the commercial segment, Miglani said, “Commercial real estate will be critical to the countrys economic development. Quality projects that can attract people are required. We are certain that our projects will change public perceptions of commercial establishments. We are committed to providing high-quality development that can lead to growth.”

The Group is also investing heavily in stuck projects to ensure that people get their promised real estate assets; earlier, it announced that it would take up five to seven stuck projects in Greater Noida and invest Rs. 4,500 crore in their construction. Miglani said, “The projects will be developed under the JV and DM models. We are pursuing township and group housing projects in the residential sector. Our strategy to resurrect stalled projects may not significantly impact new demand, but it will bring relief to dissatisfied homebuyers who have been holding their breath. Our effort is to enhance the overall consumer sentiment and help to fix the supply side.”

View article…

(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same.)